![]() ![]() New manufacturing site and scaled-up processes for Moderna’s COVID-19 vaccineĪlready last week, the CHMP recommended approving the addition of a new manufacturing site for the production of active substance and finished product intermediates for Moderna’s COVID-19 vaccine. ![]() It is expected to facilitate the rapid roll-out and distribution of the vaccine in the EU by reducing the need for ultra-low temperature cold storage conditions throughout the supply chain. This is an alternative to the long-term storage of the vials at a temperature between -90 to -60˚C in special freezers. the temperature of standard pharmaceutical freezers) for a one-off period of two weeks. In addition to the new manufacturing facility for this vaccine, the CHMP has also given a positive opinion to allow transportation and storage of vials of this vaccine at temperatures between -25 to -15˚C (i.e. There are currently three active substance manufacturing sites supplying the EU included in the marketing authorisation. ![]() The facility, which is in the German city of Marburg, will produce both active substance and the finished product. New manufacturing site and more flexible storage conditions for BioNTech/Pfizer’s COVID-19 vaccineĪ new site has also been approved for the production of Comirnaty, the COVID-19 vaccine developed by BioNTech and Pfizer. The Halix site is located in Leiden, the Netherlands, and will bring the total number of manufacturing sites licensed for the production of the active substance of the vaccine to four. New manufacturing site for AstraZeneca’s COVID-19 vaccineĪ new manufacturing site has been approved for the production of AstraZeneca’s COVID-19 vaccine active substance. EMA’s human medicines committee ( CHMP) has adopted several important recommendations that will increase manufacturing capacity and supply of COVID-19 vaccines in the EU. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |